Impact of biobanks on research outcomes in rare diseases: a systematic review

被引:27
作者
Garcia, Monique [1 ]
Downs, Jenny [2 ,3 ]
Russell, Alyce [1 ]
Wang, Wei [1 ,4 ,5 ]
机构
[1] Edith Cowan Univ, Sch Med & Hlth Sci, 270 Joondalup Dr, Perth, WA 6027, Australia
[2] Univ Western Australia, Telethon Kids Inst, Perth, WA, Australia
[3] Curtin Univ, Sch Physiotherapy & Exercise Sci, Perth, WA, Australia
[4] Capital Med Univ, Key Municipal Lab Clin Epidemiol, Beijing, Peoples R China
[5] Taishan Med Univ, Tai An, Shandong, Peoples R China
基金
中国国家自然科学基金;
关键词
Rare disease; Registries; Biobank; Systematic review; REGISTRY; BIOREPOSITORY; THERAPIES; APPROVAL; DESIGN; CANCER;
D O I
10.1186/s13023-018-0942-z
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Alleviating the burden of rare diseases requires research into new diagnostic and therapeutic strategies. We undertook a systematic review to identify and compare the impact of stand-alone registries, registries with biobanks, and rare disease biobanks on research outcomes in rare diseases. A systematic review and meta-aggregation was conducted using the preferred reporting items for systematic reviews and meta-analyses (the PRISMA statement). English language publications were sourced from PubMed, Medline, Scopus, and Web of Science. Original research papers that reported clinical, epidemiological, basic or translational research findings derived from data contained in stand-alone registries, registries with biobanks, and rare disease biobanks were considered. Articles selected for inclusion were assessed using the critical appraisal instruments by JBI-QARI. Each article was read in its entirety and findings were extracted using the online data extraction software from JBI-QARI. Thirty studies including 28 rare disease resources were included in the review. Of those, 14 registries were not associated to biobank infrastructure, 9 registries were associated with biobank infrastructure, and 6 were rare disease biobank resources. Stand-alone registries had the capacity to uncover the natural history of disease and contributed to evidence-based practice. When annexed to biobank infrastructure, registries could also identify and validate biomarkers, uncover novel genes, elucidate pathogenesis at the Omics level, and develop new therapeutic strategies. Rare disease biobanks in this review had similar capacity for biological investigations, but in addition, had far greater sample numbers and higher quality laboratory techniques for quality assurance processes. We examined the research outcomes of three specific populations: stand-alone registries, registries with biobanks, and stand-alone rare disease biobanks and demonstrated that there are key differences among these resources. These differences are a function of the resources' design, aims, and objectives, with each resource having a distinctive and important role in contributing to the body of knowledge for rare disease research. Whilst stand-alone registries had the capacity to uncover the natural history of disease, develop best practice, replace clinical trials, and improve patient outcomes, they were limited in their capacity to conduct basic research. The role of basic research in rare disease research is vital; scientists must first understand the pathways of disease before they can develop appropriate interventions. Rare disease biobanks, on the other hand (particularly larger biobanks), had the key infrastructure required to conduct basic research, making novel Omics discoveries, identify and validate biomarkers, uncover novel genes, and develop new therapeutic strategies. However, these stand-alone rare disease biobanks did not collect comprehensive data or impact on clinical observations like a rare disease registry. Rare disease research is important not only for rare diseases, but also for also common diseases. For example, research of low-density lipoprotein (LDL)-receptors in the rare disease known as familial hypercholesterolemia led to the discovery of statins, a drug therapy that is now used routinely to prevent heart disease. Rare diseases are still under-researched worldwide. This review made the important observation that registries with biobanks had the function of both stand-alone registries (the capacity to collect comprehensive clinical and epidemiological data) and stand-alone rare disease biobanks (the ability to contribute to Omics research). We found registries with biobanks offer a unique, practical, cost-effective, and impactful solution for rare disease research. Linkage of stand-alone registries to rare disease biobanks will provide the appropriate resources required for the effective translation of basic research into clinical practice. Furthermore, facilitators such as collaboration, engagement, blended recruitment, pro-active marketing, broad consent, and "virtual biobank" online catalogues will, if utilised, add to the success of these resources. These important observations can serve to direct future rare diseases research efforts, ultimately improve patient outcomes and alleviate the significant burden associated with rare disease for clinicians, hospitals, society, and most importantly, the patients and their families.
引用
收藏
页数:13
相关论文
共 52 条
  • [21] Telethon Network of Genetic Biobanks: a key service for diagnosis and research on rare diseases
    Filocamo, Mirella
    Baldo, Chiara
    Goldwurm, Stefano
    Renieri, Alessandra
    Angelini, Corrado
    Moggio, Maurizio
    Mora, Marina
    Merla, Giuseppe
    Politano, Luisa
    Garavaglia, Barbara
    Casareto, Lorena
    Bricarelli, Francesca Dagna
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2013, 8
  • [22] An evidence-based medicine model for rare and often neglected neoplastic conditions
    Fisher, Charles G.
    Goldschlager, Tony
    Boriani, Stefano
    Varga, Peter Paul
    Rhines, Laurence D.
    Fehlings, Michael G.
    Luzzati, Alessandro
    Dekutoski, Mark B.
    Reynolds, Jeremy J.
    Chou, Dean
    Berven, Sigurd H.
    Williams, Richard P.
    Quraishi, Nasir A.
    Bettegowda, Chetan
    Gokaslan, Ziya L.
    [J]. JOURNAL OF NEUROSURGERY-SPINE, 2014, 21 (05) : 704 - 710
  • [23] miR-1254 and miR-574-5p Serum-Based microRNA Biomarkers for Early-Stage Non-small Cell Lung Cancer
    Foss, Kristen M.
    Sima, Chao
    Ugolini, Donatella
    Neri, Monica
    Allen, Kristi E.
    Weiss, Glen J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (03) : 482 - 488
  • [24] Pragmatism as the philosophical foundation for the Joanna Briggs meta-aggregative approach to qualitative evidence synthesis
    Hannes, Karin
    Lockwood, Craig
    [J]. JOURNAL OF ADVANCED NURSING, 2011, 67 (07) : 1632 - 1642
  • [25] If you build a rare disease registry, will they enroll and will they use it? Methods and data from the National Registry of Myotonic Dystrophy (DM) and Facioscapulohumeral Muscular Dystrophy (FSHD)
    Hilbert, James E.
    Kissel, John T.
    Luebbe, Elizabeth A.
    Martens, William B.
    McDermott, Michael P.
    Sanders, Donald B.
    Tawil, Rabi
    Thornton, Charles A.
    Moxley, Richard T., III
    [J]. CONTEMPORARY CLINICAL TRIALS, 2012, 33 (02) : 302 - 311
  • [26] Novel Approaches to Corticoid Treatment in Duchenne Muscular Dystrophy
    Hoffman, Eric P.
    Reeves, Erica
    Damsker, Jesse
    Nagaraju, Kanneboyina
    McCall, John M.
    Connor, Edward M.
    Bushby, Kate
    [J]. PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA, 2012, 23 (04) : 821 - +
  • [27] Call for a national plan for rare diseases
    Jaffe, Adam
    Zurynski, Yvonne
    Beville, Lyndall
    Elliott, Elizabeth
    [J]. JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2010, 46 (1-2) : 2 - 4
  • [28] Recommendations for the development of rare disease drugs using the accelerated approval pathway and for qualifying biomarkers as primary endpoints
    Kakkis, Emil D.
    O'Donovan, Mary
    Cox, Gerald
    Hayes, Mark
    Goodsaid, Federico
    Tandon, P. K.
    Furlong, Pat
    Boynton, Susan
    Bozic, Mladen
    Orfali, May
    Thornton, Mark
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2015, 10
  • [29] The CNDR: Collaborating to Translate New Therapies for Canadians
    Korngut, Lawrence
    Campbell, Craig
    Johnston, Megan
    Benstead, Timothy
    Genge, Angela
    MacKenzie, Alex
    McCormick, Anna
    Biggar, Douglas
    Bourque, Pierre
    Briemberg, Hannah
    O'Connell, Colleen
    Dojeiji, Suzan
    Dooley, Joseph
    Grant, Ian
    Hogan, Gillian
    Johnston, Wendy
    Kalra, Sanjay
    Katzberg, Hans D.
    Mah, Jean K.
    McAdam, Laura
    McMillan, Hugh J.
    Melanson, Michel
    Selby, Kathryn
    Shoesmith, Christen
    Smith, Garth
    Venance, Shannon L.
    Wee, Joy
    [J]. CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2013, 40 (05) : 698 - 704
  • [30] Establishment and Maintenance of Primary Fibroblast Repositories for Rare DiseasesFriedreich's Ataxia Example
    Li, Yanjie
    Polak, Urszula
    Clark, Amanda D.
    Bhalla, Angela D.
    Chen, Yu-Yun
    Li, Jixue
    Farmer, Jennifer
    Seyer, Lauren
    Lynch, David
    Butler, Jill S.
    Napierala, Marek
    [J]. BIOPRESERVATION AND BIOBANKING, 2016, 14 (04) : 324 - 329